Biomarin Pharmaceutical Inc
NASDAQ:BMRN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.93
99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc
Revenue
Biomarin Pharmaceutical Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
Revenue
$2.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Biomarin Pharmaceutical Inc
Revenue Breakdown
Breakdown by Geography
Biomarin Pharmaceutical Inc
Breakdown by Segments
Biomarin Pharmaceutical Inc
|
Total Revenue:
2.4B
USD
|
|
Net Product Revenues:
2.4B
USD
|
|
Products Excluding Aldurazyme:
2.2B
USD
|
|
Aldurazyme:
131.2m
USD
|
|
Royalty And Other Revenues:
46.7m
USD
|
Biomarin Pharmaceutical Inc
Glance View
BioMarin Pharmaceutical Inc. is a leading biotechnology company that has carved out a niche in developing innovative therapies for rare genetic disorders. Founded in 1997 and headquartered in San Rafael, California, BioMarin has a mission driven by compassion and commitment to patient care. The company has made remarkable strides in advancing treatments for conditions that often lack effective medical options, such as Phenylketonuria (PKU) and mucopolysaccharidoses (MPS). With a robust pipeline of drugs, BioMarin's portfolio includes several approved therapies like Vimizim and Brineura, which are testament to their dedication to addressing unmet medical needs. With a focus on science and research, BioMarin aims to not only enhance quality of life for patients but also to ensure sustainable growth for its investors. As an investor, understanding BioMarin means recognizing its potential for long-term value based on innovation and market opportunities. The company is strategically positioned in a rapidly growing sector of personalized medicine, which is increasingly drawing attention as health systems embrace targeted treatments. BioMarin's commitment to R&D is evident in its ongoing clinical trials and collaborations with healthcare professionals and institutions, paving the way for future therapies and potentially transformative treatments. With the global rare disease market expanding, BioMarin stands at the forefront, ready to leverage its expertise and intellectual property to drive revenue growth. For investors, BioMarin represents not just a company with promising financials but also one with a profound impact on patient lives, making it an attractive proposition for those seeking both profit and purpose in their investments.
See Also
What is Biomarin Pharmaceutical Inc's Revenue?
Revenue
2.8B
USD
Based on the financial report for Sep 30, 2024, Biomarin Pharmaceutical Inc's Revenue amounts to 2.8B USD.
What is Biomarin Pharmaceutical Inc's Revenue growth rate?
Revenue CAGR 10Y
15%
Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Biomarin Pharmaceutical Inc have been 14% over the past three years , 11% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
